CRISPR Therapeutics AG announced its financial results for the fourth quarter and full year ended December 31, 2025, reporting CASGEVY revenue of $54 million for Q4 2025 and $116 million for full year 2025, and a net loss of $130.6 million for Q4 2025. The company also provided business updates across its clinical pipeline including CASGEVY, in vivo liver editing programs, siRNA-based programs, and autoimmune/oncology programs.
Key takeaways
CASGEVY generated Q4 2025 revenue of $54 million and full year 2025 revenue of $116 million, with 64 patients receiving infusions during the year including 30 in Q4.
Net loss was $130.6 million for Q4 2025 compared to $37.3 million for Q4 2024, with increased collaboration expense due to absence of cost deferral.
Cash, cash equivalents, and marketable securities were $1,975.8 million as of December 31, 2025, compared to $1,903.8 million as of December 31, 2024.
R&D expenses were $83.5 million for Q4 2025 compared to $71.7 million for Q4 2024, primarily driven by increased licensing fees.
CASGEVY is now approved in multiple regions including U.S., EU, Great Britain, Canada, Switzerland, KSA, Bahrain, Qatar, UAE, and Kuwait for patients 12+ with SCD or TDT.
The company expects to begin global regulatory submissions for CASGEVY in pediatric patients (ages 5-11) in the first half of 2026, with FDA awarding a Commissioner's National Priority Voucher.